THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE
Top Cited Papers
- 1 July 2003
- journal article
- guideline
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 31 (7), 815-832
- https://doi.org/10.1124/dmd.31.7.815
Abstract
Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs. There is also a growing consensus for the standardization of cytochrome P450 (P450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients. While existing guidances cover mainly P450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed. This article was prepared by the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism and Clinical Pharmacology Technical Working Groups and represents the current industry position. The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compound registration dossiers.Keywords
This publication has 62 references indexed in Scilit:
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- The Pharmacokinetics of LevosalbutamolClinical Pharmacokinetics, 2001
- Implications and consequences of enzyme induction on preclinical and clinical drug developmentXenobiotica, 2001
- Induction of Drug Metabolising EnzymesClinical Pharmacokinetics, 2000
- High and variable frequencies of CYP2C19 mutationsPharmacogenetics and Genomics, 1999
- The effect of grapefruit juice (GFJ) on plasma levels of simvastatin HMG-CoA reductase inhibitorsAtherosclerosis, 1999
- Induction of CYP3A isoforms in cultured precisioncut human liver slicesXenobiotica, 1997
- Induction of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slicesXenobiotica, 1996
- Assessment of Liver Metabolic FunctionClinical Pharmacokinetics, 1994
- Evidence for a Polarized Efflux System in Caco-2 Cells Capable of Modulating Cyclosporine A TransportBiochemical and Biophysical Research Communications, 1993